Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...
Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
US FDA grants Orphan Drug Designation to Adolore BioTherapeutics’ Kv7-activating rdHSV-CA8 therapy to treat erythromelalgia: Delray Beach, Florida Friday, January 16, 2026, 17:0 ...
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Last week, biotechnology company Ascidian Therapeutics announced a manufacturing partnership with gene-therapy–focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback